Bone-directed therapy and breast cancer: Bisphosphonates, monoclonal antibodies, and radionuclides [10.1007/978-3-319-26012-9_42]

Basit Öğe Kaydı
dc.authorscopusid7006046625
dc.authorscopusid8922379100
dc.contributor.authorErdogan B.
dc.contributor.authorCicin I.
dc.date.accessioned2024-06-12T10:24:47Z
dc.date.available2024-06-12T10:24:47Z
dc.date.issued2016
dc.description.abstractBreast cancer bone metastasis causes severe morbidity and is commonly encountered in daily clinical practice. It causes pain, pathologic fractures, spinal cord and other nerve compression syndromes and life-threatening hypercalcemia. Breast cancer metastasizes to the bone through a complicated process that involves numerous molecules. Metastatic cells disrupt normal bone turnover and create a vicious cycle. All treatment effort is directed to breaking this vicious cycle. Bisphosphonates have been used safely for more than two decades. As a group, bisphosphonates delay the time to the first skeletal-related event and reduce pain. However, they do not prevent the development of bone metastasis in patients with no bone metastasis and do not prolong survival. The receptor activator for nuclear factor ?B ligand inhibitor denosumab also delays the time to the first skeletal-related event and reduces the skeletal morbidity rate. Radionuclides are another treatment option for bone pain. © Springer International Publishing Switzerland 2016.en_US
dc.identifier.doi10.1007/978-3-319-26012-9_42
dc.identifier.endpage709en_US
dc.identifier.isbn9783319260129
dc.identifier.isbn9783319260105
dc.identifier.scopus2-s2.0-85025468884en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage695en_US
dc.identifier.urihttps://doi.org/10.1007/978-3-319-26012-9_42
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16017
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer International Publishingen_US
dc.relation.ispartofBreast Disease: Management and Therapiesen_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBisphosphonate; Cadherin-11; Cathepsin K; Clodronate; Conjunctivitis; Dasatinib; Denosumab; E-Selectin; Episcleritis; Farnesyl Pyrophosphate Synthase Enzyme; Hypocalcemia; Ibandronate; Insulin-Like Growth Factor 1 (Igf1); Interleukin 11 (Il-11); Interleukin 6 (Il-6); Intracellular Adhesion Molecule (Icam-1); Iritis. Strontium-89 Hydrochloride (Sr-89); Macrophage Colony-Stimulating Factor (M-Csf); Mevalonate Pathway; Nephrotoxicity; Odanacatib; Osteonecrosis Of The Jaw (Onj); P-Selectin; Pamidronate; Parathyroid Hormonerelated Peptide (Pthrp); Phosphorus-32 (P-32); Prenylation; Prostaglandin E2 (Pge2); Radionuclide; Rhenium-186 Hydroxyethylidene Diphosphonate (Re-186); Samarium-153 Lexidronam (Sm-153); Saracatinib; Scleritis; Src; Uveitis; Vascular Cell Adhesion Molecule (Vcam-1); Zoledronic Acid; ???3 Integrinen_US
dc.titleBone-directed therapy and breast cancer: Bisphosphonates, monoclonal antibodies, and radionuclides [10.1007/978-3-319-26012-9_42]en_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu